...
首页> 外文期刊>Journal of Medicinal Chemistry >CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia
【24h】

CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia

机译:CC-90009:促进GSPT1的选择性降解急性髓细胞白血病的选择性降解

获取原文
获取原文并翻译 | 示例
           

摘要

Acute myeloid leukemia (AML) is marked by significant unmet clinical need due to both poor survival and high relapse rates where long-term disease control for most patients with relapsed or refractory AML remain dismal. Inspired to bring novel therapeutic options to these patients, we envisioned protein degradation as a potential therapeutic approach for the treatment of AML. Following this course, we discovered and pioneered a novel mechanism of action which culminated in the discovery of CC-90009. CC-90009 represents a novel protein degrader and the first cereblon E3 ligase modulating drug to enter clinical development that specifically targets GSPT1 (G1 to S phase transition 1) for proteasomal degradation. This manuscript briefly summarizes the mechanism of action, scientific rationale, medicinal chemistry, pharmacokinetic properties, and efficacy data for CC-90009, which is currently in phase 1 clinical development.
机译:急性髓系白血病(AML)的特点是,由于生存率低和复发率高,大多数复发或难治性AML患者的长期疾病控制仍然不理想,临床需求严重得不到满足。为了给这些患者带来新的治疗选择,我们设想蛋白降解是治疗AML的一种潜在治疗方法。在这门课程之后,我们发现并开创了一种新的作用机制,最终发现了CC-90009。CC-90009是一种新型的蛋白质降解剂,也是第一种进入临床开发阶段的cereblon E3连接酶调节药物,它专门针对GSPT1(G1到S相变1)进行蛋白酶体降解。本手稿简要总结了CC-90009的作用机制、科学原理、药物化学、药代动力学特性和疗效数据,目前CC-90009正处于1期临床开发阶段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号